NFLUENTIAL DRUG PRICING PANEL SEES NO BENEFIT FROM ADUHELM — An expert panel convened by the Institute for Clinical and Economic Review concluded Thursday that the controversial Alzheimer's drug does not work better than existing forms of care — and isn’t worth Biogen’s $56,000 price tag. The group rendered its verdict as a unanimous vote at a meeting reviewing Aduhelm, which FDA approved last month.
“Looking at the data, if I had to guess, the data is stronger for net harm than it is for net benefit,” said Sai Lee, a geriatrician at the University of California San Francisco and one of 15 voting members of Thursday’s panel.
Though ICER can’t determine drug prices, it can influence lawmakers and other stakeholders who do. Currently, CMS is meeting to discuss whether Medicare will cover the drug.
“Looking at the data, if I had to guess, the data is stronger for net harm than it is for net benefit,” said Sai Lee, a geriatrician at the University of California San Francisco and one of 15 voting members of Thursday’s panel.
Though ICER can’t determine drug prices, it can influence lawmakers and other stakeholders who do. Currently, CMS is meeting to discuss whether Medicare will cover the drug.